retatrutide type 2 diabetes trial 2024 improves blood sugar and weight loss in retatrutide phase 2 trial type

Key highlights Semaglutide is a glucagon-like peptide-1 receptor agonist that works on GLP-1 receptors in the body to manage blood glucose levels and lose weight by delaying gastric emptying and reducing appetite

Diabetes 41 , 467473 (2023)

When it comes to picking which part of the body to inject into, it is best to select a fleshy area where the skin is thick and that is well away from veins and muscles

Cases involving diagnosed gastroparesis, bowel obstruction, hospitalization, emergency surgery, or long-term digestive impairment may carry projected settlement values ranging from approximately $150,000 to $700,000 or more

Current animal studies show potential fetal risks, which is why major health organizations recommend discontinuing GLP-1 therapy three months before attempting conception

Are GLP-1s safe for long-term use